-0.85%
-9.16%
3.56%
-8.09%
60.41%
77.52%
167.20%
AI Spotlight on XVIVO
Company Description
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific.The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP.It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP.
In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product.The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
Market Data
| Last Price | 466 |
| Change Percentage | -0.85% |
| Open | 469 |
| Previous Close | 470 |
| Market Cap ( Millions) | 14679 |
| Volume | 48475 |
| Year High | 547 |
| Year Low | 252.5 |
| M A 50 | 466.45 |
| M A 200 | 463.61 |
Financial Ratios
| FCF Yield | 0.50% |
| Dividend Yield | 0.00% |
| ROE | 8.33% |
| Debt / Equity | 0.00% |
| Net Debt / EBIDTA | -359.39% |
| Price To Book | 6.81 |
| Price Earnings Ratio | 85.25 |
| Price To FCF | 199.47 |
| Price To sales | 17.85 |
| EV / EBITDA | 123.36 |
News
- Jan -28 - Year-End Report 2024
- Jan -13 - Conference Call on Year-End Report 2024
- Dec -13 - Xvivo Perfusion And 2 More Stocks Estimated To Be Trading Below Their Intrinsic Value
- Nov -25 - Enrollment Completed Five Months Early in the US Clinical Trial Evaluating XVIVOs Heart Preservation Technology
- Nov -21 - 3 Undervalued Small Caps With Insider Buying Across Regions
- Nov -14 - XVIVO Perfusion Appoints Lena Hagman as Deputy CEO
- Nov -12 - 3 Stocks Estimated To Be Trading Up To 42.3% Below Intrinsic Value
- Nov -03 - Worldline (ENXTPA:WLN) Eyes Recovery with AI Alliances Despite Index Exclusions and Revenue Challenges
- Oct -24 - Interim Report January-September 2024
- Oct -10 - Conference Call on Interim Report
- Sep -19 - XVIVO to Acquire a Unique Communication Platform for the Transplant Process
- Sep -06 - Nomination Committee of XVIVO Perfusion AB (publ)
- Aug -16 - Results From European Randomized Controlled Study Using XVIVO's Heart Technology Published in The Lancet
- Aug -05 - Absolent Air Care Group And 2 Other Stocks On The Swedish Exchange Possibly Undervalued
- Jul -19 - Three Swedish Exchange Stocks Estimated To Be Up To 25.5% Below Intrinsic Value Estimates
- Jul -16 - Exploring Undervalued Stocks On The Swedish Exchange With Discounts Ranging From 15.3% To 24.4%
- Jul -15 - Husqvarna And Two More Swedish Exchange Stocks Considered Undervalued By Market Estimates
- Jul -12 - Interim Report January - June 2024
- Jul -11 - Biotage And Two Other Swedish Exchange Stocks Estimated As Undervalued
- Jul -10 - Exploring Undervalued Swedish Stocks On The Exchange With Discounts Ranging From 18% To 27.7%
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Thoracic
Expected Growth : 8.5 %
What the company do ?
Thoracic is a lung preservation technology from Xvivo Perfusion AB, allowing for ex-vivo lung perfusion and evaluation, increasing the availability of lungs for transplantation.
Why we expect these perspectives ?
Thoracic segment's 8.5% growth is driven by increasing adoption of Ex Vivo Lung Perfusion (EVLP) technology, rising lung transplantation rates, and growing demand for high-quality organs. Additionally, Xvivo Perfusion's innovative products and services, such as the XPS and STEEN Solution, are expanding the addressable market and driving revenue growth.
Segment n°2 -> Abdominal
Expected Growth : 8.5 %
What the company do ?
The Abdominal from Xvivo Perfusion AB (publ) is a medical device designed to preserve and transport organs for transplantation, specifically focused on abdominal organs.
Why we expect these perspectives ?
Xvivo Perfusion AB's abdominal segment growth of 8.5% is driven by increasing demand for organ preservation and transplantation, advancements in perfusion technology, and expansion into new markets. Additionally, growing awareness of organ donation and government initiatives to increase transplantation rates contribute to the segment's growth.
Segment n°3 -> Services
Expected Growth : 9.03 %
What the company do ?
Xvivo Perfusion AB (publ) offers services in ex-vivo lung perfusion, enabling the assessment and reconditioning of donor lungs, increasing the availability of lungs for transplantation.
Why we expect these perspectives ?
Xvivo Perfusion AB's 9.03% growth is driven by increasing demand for organ preservation and transplantation, expansion into new markets, and strategic partnerships. The company's innovative perfusion technology and growing presence in the transplant market also contribute to its growth. Additionally, the rising need for organs and tissues, coupled with advancements in medical technology, further fuel the company's expansion.
Xvivo Perfusion Ab (Publ) Products
| Product Range | What is it ? |
|---|---|
| XPS | XPS is a heart preservation system designed to optimize the preservation of donor hearts for transplantation. |
| STEEN Solution | A specialized preservation solution used to optimize the preservation of organs for transplantation. |
| Xvivo Perfusion System | A system designed to optimize the preservation and transportation of organs for transplantation. |
| Liver Assist | A system designed to optimize the preservation and reconditioning of livers for transplantation. |
| Lung Assist | A system designed to optimize the preservation and reconditioning of lungs for transplantation. |
Xvivo Perfusion AB (publ)'s Porter Forces
Threat Of Substitutes
Xvivo Perfusion AB (publ) operates in a niche market with limited substitutes, but there are some alternatives available, which reduces the threat of substitutes.
Bargaining Power Of Customers
The company's customers are primarily hospitals and research institutions, which have limited bargaining power due to the specialized nature of Xvivo's products.
Bargaining Power Of Suppliers
Xvivo Perfusion AB (publ) relies on a few key suppliers for its raw materials, which gives them some bargaining power, but the company's strong relationships with suppliers mitigate this risk.
Threat Of New Entrants
The barriers to entry in the organ preservation and perfusion market are relatively high, making it difficult for new entrants to compete with Xvivo Perfusion AB (publ)'s established products and expertise.
Intensity Of Rivalry
The organ preservation and perfusion market is moderately competitive, with a few established players, but Xvivo Perfusion AB (publ) has a strong market position and differentiated products.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 1.59% |
| Debt Cost | 3.95% |
| Equity Weight | 98.41% |
| Equity Cost | 13.90% |
| WACC | 13.74% |
| Leverage | 1.62% |
Xvivo Perfusion AB (publ) : Quality Control
Xvivo Perfusion AB (publ) passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| INMD | InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and … |
| CEVI.ST | CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the … |
| REG1V.HE | Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics and devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of … |
| MEDI.OL | Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound … |
| LFWD | ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Revenio
A-Score
1-Year Total Return ->
🥈
InMode
A-Score
1-Year Total Return ->
🥉
CellaVision
A-Score
1-Year Total Return ->
4
Medistim
A-Score
1-Year Total Return ->
5
Xvivo Perfusion
A-Score
1-Year Total Return ->
6
